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Abstract
Matriptase is a member of the family of type II transmembrane serine proteases that is essential for development and
maintenance of several epithelial tissues. Matriptase is synthesized as a single-chain zymogen precursor that is processed
into a two-chain disulfide-linked form dependent on its own catalytic activity leading to the hypothesis that matriptase
functions at the pinnacle of several protease induced signal cascades. Matriptase is usually found in either its zymogen form
or in a complex with its cognate inhibitor hepatocyte growth factor activator inhibitor 1 (HAI-1), whereas the active non-
inhibited form has been difficult to detect. In this study, we have developed an assay to detect enzymatically active non-
inhibitor-complexed matriptase by using a biotinylated peptide substrate-based chloromethyl ketone (CMK) inhibitor.
Covalently CMK peptide-bound matriptase is detected by streptavidin pull-down and subsequent analysis by Western
blotting. This study presents a novel assay for detection of enzymatically active matriptase in living human and murine cells.
The assay can be applied to a variety of cell systems and species.
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Introduction
Matriptase (also known as MT-SP1, epithin, TADG-15 and
SNC19) is a type II transmembrane serine protease that is
expressed in most epithelia and has pleiotropic roles in epithelial
development and homeostasis [1–5]. Matriptase is a multi-
modular, approximately 95 kDa protease that consists of a short
cytoplasmic N-terminal peptide, a signal anchor that functions as a
single-pass transmembrane domain, a sea urchin sperm protein,
enteropeptidase, agrin (SEA) domain, two complement C1r/s
urchin embryonic growth factor and bone morphogenetic protein-
1 (CUB) domains, four low-density lipoprotein receptor class A
(LDLRA) domains, and a trypsin-like serine protease domain
(SPD) [6,7].
Matriptase, like other trypsin-like serine proteases, is synthesized
as a catalytically inactive, single chain protein (zymogen). The
activation of matriptase zymogen (also termed zymogen conver-
sion) is extraordinarily complex and still incompletely understood
at the mechanistic level. Matriptase activation involves two
sequential endoproteolytic cleavages, and may also require
transient interactions with its cognate inhibitor, hepatocyte growth
factor activator inhibitor (HAI)-1 [7,8] [reviewed in [9,10]] or
HAI-2 [11]. Full-length matriptase is first hydrolysed at the
Gly149-Ser150 peptide bond, which is located in a conserved
GSVIA motif within the SEA domain, whereby the SEA
domain-cleaved zymogen form is generated. The protease remains
attached to the membrane by strong non-covalent interactions
within the cleaved SEA domain. The SEA domain cleavage
appears to occur within the secretory pathway, as only the SEA
domain-cleaved form of the protease is present on the surface of
cells [12]. Matriptase is next converted into its active conformation
by proteolytic cleavage after Arg614 within the conserved
activation cleavage site R-VVGG located within the serine
protease domain. Importantly, this cleavage has been reported
to require the proteolytic activity of matriptase, as mutations in
any of the residues of the catalytic triad renders matriptase unable
to undergo activation site cleavage. This finding has led to a model
for matriptase activation in which a weak intrinsic proteolytic
activity of the SEA domain-cleaved matriptase zymogen activates
neighboring SEA domain-cleaved matriptase molecules [7].
Consistent with this model, the purified SEA domain-cleaved
soluble matriptase has been shown to be capable of hydrolyzing
synthetic peptide substrates in solution, although catalytic activity
of the cell surface matriptase zymogen still needs to be
demonstrated [13,14].
The capacity of matriptase zymogen to autoactivate is unusual
and has led to the proposal that matriptase serves as an initiator of
proteolytic cascades. Indeed, matriptase has been shown to
facilitate activation of the urokinase plasminogen activation
cascade, of epidermal kallikreins, and of the GPI-anchored serine
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protease, prostasin [15–17]. Recent studies, however, have
unexpectedly shown that matriptase activation in some contexts
is critically dependent on prostasin [18–20]. This suggests that
prostasin may directly mediate the activation site cleavage of
matriptase, that matriptase activates an unidentified ternary
matriptase-activating protease or that prostasin serves as a non-
enzymatic allosteric co-factor for matriptase autoactivation. The
specific physiological mechanisms that trigger the complex series
of events leading to the activation of matriptase are also poorly
understood. In cultured cells, matriptase activation has been
reported to occur in response to exposure to sphingosine-1-
phosphate, suramin, androgens, low pH, and either soluble or
membrane-anchored prostasin [19,21–27].
The absence of probes to specifically detect active non-inhibitor
complexed matriptase in situ has been a principal obstacle in
unraveling the complex biochemistry of the protease. In this
paper, we have combined antibody specificity with the high
affinity of biotin-streptavidin interaction to design a peptide
inhibitor-based assay for the detection of matriptase activity.
Specifically, we have engineered a chloromethyl ketone-based
tetra-peptide with an N-terminal biotin moiety that allows for the
segregation of non-reacting proteins, including forms of matriptase
that are not able to bind the peptide. Specificity of the assay is
obtained by Western blot analysis employing specific antibodies
against matriptase. We validate the probe in human and murine
cell-based models, show that active matriptase represent only a
minor fraction of total cell surface matriptase, and demonstrate
that cell surface matriptase zymogen is catalytically active.
Materials and Methods
Chromogenic assay
Matriptase SPD expressed and purified from P. pastoris [28] was
prepared in 20 mM Hepes pH 7.4, 140 mM NaCl supplemented
with 0.1% BSA (Sigma-Aldrich, Copenhagen, Denmark) and
100 ml was added to wells of a 96 well plate at a concentration of
0.4 nM. Stocks of varying concentrations (5 nM or 50 mM) of
biotin-Arg-Gln-Arg-Arg-CMK (biotin-RQRR-CMK) peptide
(American Peptide, Derbyshire, UK) were incubated in the same
buffer at 37uC for up to 3 h. At specific time points, 100 ml of
inhibitor solution was added to the well containing the active
catalytic domain of matriptase. Following additional 10 min
incubation at 37uC, 10 ml 6.3 mM chromogenic substrate H-D-
Isoleucil-L-prolyl-L-arginine-p-nitroaniline (cat. no. S2288, Chro-
mogenix, Essen, Germany) was added and substrate conversion
was followed in a standard plate reader by 30 min continuous
measurements of the absorbance at 405 nm at 37uC. The rate of
substrate turnover was determined from the slope of the
corresponding curve of color development resulting from a pseudo
first order reaction. To test pH effects on substrate turnover and
biotin-RQRR-biotin binding efficiency, the buffer component of
the assay was changed from Hepes, pH 7.4 to 20 mM Citric acid
pH 6.0.
Cell culture
The human colon epithelial cell line Caco-2 [29] was grown in
Dulbecco’s modified Eagle medium supplemented with 2 mM L-
glutamine, 20% fetal bovine serum (Gibco, Copenhagen, Den-
mark), 16 non-essential amino acids, 100 units/ml penicillin and
100 mg/ml streptomycin (Invitrogen, Copenhagen, Denmark) at
37uC in an atmosphere of 5% CO2. For all experiments, 1–2610
6
cells were seeded into 35 mm tissue culture plates or 0.4 mm-pore-
size 24 mm TranswellH filters (Corning, Copenhagen, Denmark)
allowing separate access to the apical and the basolateral plasma
membrane. The cell culture medium was changed every day.
Filter-grown cells were cultivated until 11 days post-confluence
before they were used in experiments. The tightness of filter-grown
cells was assayed by filling the inner chamber to the brim and
allowing it to equilibrate overnight.
Ethics Statement
All animal work was performed in accordance with protocols
approved by the National Institute of Dental and Craniofacial
Research Animal Care and Use Committee (Animal Study
Proposal Number: 10-577).
Isolation and short-term culture of primary keratinocytes
from newborn mice
Epidermis was isolated from newborn mice (p1-2) and grown in
culture as previous described [30]. Briefly, newborn pups were
euthanized by decapitation and the torso was submerged in
betadine and ethanol to sterilize the skin. The skin was incubated
in 0.25% trypsin w/o EDTA (Sigma-Aldrich) o/N at 4uC. The
dermal portion was discarded, and the epidermis was minced to
release keratinocytes. The minced epidermis was resuspended in
45 mM Ca2+/10% FBS/Keratinocyte-SFM (Invitrogen) media
and was filtered through a 100 mm cell strainer and centrifuged to
remove stratum corneum pieces. The cell pellet was resuspended
in low calcium medium (45 mM Ca2+/Keratinocyte-SFM media)
and plated in culture plates coated with collagen I (BD
Biosciences, New Jersey, USA). Cells were grown in low calcium
medium to sub-confluence and cell culture medium was changed
every second day.
Labeling with biotin-Arg-Gln-Arg-Arg-chloromethyl
ketone (biotin-RQRR-CMK) peptide inhibitor and S-NHS-
SS-biotin
Cells were washed twice; filter-grown Caco-2 cells with PBS++
(PBS supplemented with 0.7 mM CaCl2 and 0.25 mM MgCl2)
and primary murine keratinocytes with PBS. For labeling of active
matriptase, cells were incubated with 50 mM biotin-RQRR-CMK
(American Peptide) in serum-free minimal essential medium
(MEM) eagle with Earle’s supplemented with 0.2% NaHCO3,
100 units/ml penicillin and 100 mg/ml streptomycin (Invitrogen)
at 37uC for the times indicated. As a negative control, cells were
treated with 50 mM of a corresponding peptide without a CMK
group; biotin-Arg-Gln-Arg-Arg (biotin-RQRR). Peptides were
prepared as 50 mM stocks in DMSO and were stored at
220uC. For acid-induced activation of matriptase, cells were
labeled in a physiological phosphate buffer (25 mM Na2HPO4,
175 mM NaH2PO4) pH 6.0 or pre-treated with physiological
phosphate buffer pH 6.0 before labeling in serum-free MEM eagle
with Earle’s supplemented with 0.2% NaHCO3, 100 units/ml
penicillin and 100 mg/ml streptomycin. For labeling of surface
proteins, cells were biotinylated from the basolateral side with
1 mg/ml EZ-linkTM Sulfo-NHS-SS-Biotin (Pierce) dissolved in
PBS++ for 30 min at 4uC as previously described [31]. After
peptide- and/or ordinary biotin-labeling, the cells were washed
four times with ice-cold PBS++. For biotin-labeling, residual biotin
was quenched with 50 mM glycine/PBS++ for 5 min at 4uC and
the cells were washed twice with PBS++. Cells were lysed in PBS
containing 1% Triton X-100, 0.5% deoxycholate and protease
inhibitors (10 mg/l benzamidine, 2 mg/l pepstatin A, 2 mg/l
leupeptin, 2 mg/l antipain, and 2 mg/l chymostatin). Insoluble
material was precipitated at 20,0006g for 20 min at 4uC and equal
amounts of supernatants were transferred to clean Eppendorf
tubes.
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Streptavidin pull down
Cleared lysates were incubated for 2 h with end-over-end
rotation at 4uC with 50 ml/24 mm filter pre-washed streptavidin-
coated resin (Pierce), prepared as described by manufacturer. The
streptavidin-coated resin was washed four times with 25 mM
TRIS-HCl, 500 mM NaCl, 0.5% Triton X-100, pH 7.8, and
three times with 10 mM TRIS-HCl, 150 mM NaCl, pH 7.8.
Biotinylated proteins were eluted from the streptavidin-coated
resin by boiling in SDS sample buffer.
SDS-PAGE and Western blotting
Proteins were separated on 10% acrylamide gels and transferred
to Immobilon-P PVDF membranes (Millipore, Copenhagen,
Denmark). The membranes were blocked with 10% non-fat dry
milk in PBS containing 0.1% Tween-20 (PBS-T) for 1 hr at RT
and were probed with primary antibody diluted in 1% non-fat dry
milk in PBS-T at 4uC o/N. The next day the membranes were
washed 3 times with PBS-T, followed by detection of bound
primary antibody with horseradish peroxidase (HRP)-conjugated
secondary antibody (Pierce) or alkaline phosphatase (AP)-conju-
gated secondary antibody (Sigma-Aldrich). After 3 washes with
PBS-T, the signal was developed using the ECL reagent Super
Signal West Femto Maximum Sensitivity Substrate (Pierce) for
HRP-conjugated secondary antibodies according to the protocol
supplied by the manufacturer and visualized with a Fuji LAS1000
camera (Fujifilm, Stockholm, Sweden) or by nitro-blue tetrazolium
and 5- bromo-4-chloro-39-indolyphosphate (Pierce) according to
the protocol supplied by the manufacturer for AP-conjugated
secondary antibody.
Antibodies
The antibodies used for detection of matriptase in Western
blotting were monoclonal mouse anti-human matriptase antibody
M32 or monoclonal mouse anti-human matriptase antibody M24
(1 mg/ml 1% milk in PBS-T), which detects a 70 kDa band
(representing both active and zymogen matriptase both in boiled
and non-boiled samples) and the 120–130 kDa complex of
matriptase with HAI-1, which can only be detected in non-boiled
samples [32]; monoclonal mouse anti-human matriptase antibody
M69 (1 mg/ml 1% milk in PBS-T), which recognizes the 120–
130 kDa complex of matriptase with HAI-1 [32]; monoclonal
mouse anti-human HAI-1 antibody M19 (1 mg/ml 1% milk in
PBS-T), which recognizes free 55 kDa HAI-1 and the 120–
130 kDa matriptase-HAI-1 complex [32]; polyclonal rabbit anti-
human matriptase (1.5 mg/ml 1% milk in PBS-T) raised against
the SPD of matriptase recognizing a 70 kDa band (both active and
zymogen matriptase) under non-reducing conditions and the
70 kDa zymogen form and the 30 kDa serine protease domain of
cleaved matriptase under reducing conditions (Cat. no. IM1014,
Calbiochem). For detection of matriptase in murine cells, sheep
anti-matriptase was used (AF3946 diluted 1:1000, R&D). Second-
ary antibodies include goat anti-mouse HRP-conjugated (2 ng/ml
1% milk in PBS-T) (Pierce), goat anti-rabbit HRP-conjugated
(1.5 mg/ml 1% milk in PBS-T) (Pierce) and donkey anti-sheep AP-
conjugated (2 ng/ml 1% milk in PBS-T) (Sigma-Aldrich).
Results
Biotin-RQRR-CMK peptide inhibitor designed to react
with active matriptase
In order to detect active matriptase, we designed the peptide-
based probe, biotin-RQRR-CMK, consisting of a tetra-peptide;
RQRR with an N-terminal biotin moiety and a C-terminal CMK
group (figure 1A). This inhibitor was designed based on a
preferred substrate sequence of matriptase [33]. The CMK group
ensures that the protease-peptide interaction results in the
formation of a covalent bond between the peptide and the
protease, thereby attaching a biotin moiety to the now inactivated
enzyme [34]. In a complex media, the biotin group allows for
efficient isolation of biotin-RQRR-CMK-labeled proteases and
endogenously biotinylated proteins by streptavidin precipitation,
whereby catalytically-inactive matriptase not able to bind the
substrate is segregated away [35].
Biotin-RQRR-CMK inhibits the proteolytic activity of
matriptase SPD in vitro
To verify that biotin-RQRR-CMK binds and inhibits matrip-
tase, we tested whether the peptide inhibitor was able to block the
hydrolysis of a chromogenic substrate by recombinant matriptase
SPD. Although matriptase has a pH optimum at pH 9 [33], this
assay was performed at pH 7.4 in order to mimic the conditions
on the plasma membrane. We found that 50 mM biotin-RQRR-
CMK renders 0.2 nM matriptase SPD unable to cleave the
chromogenic substrate (figure 1B, crosses), whereas matriptase
SPD in the absence of biotin-RQRR-CMK cleaved the substrate
efficiently (figure 1B, squares). Chloromethyl ketones are known to
be hydrolyzed in aqueous solutions often with a half life 5–20 min
[34]. To test the stability of the inhibitor, 50 mM biotin-RQRR-
CMK was pre-incubated in aqueous solution at 37uC for 180 min
before being added to the matriptase SPD. We found that the
remaining active fraction of the pre-incubated biotin-RQRR-
CMK is still sufficient to efficiently inhibit the activity of 0.2 nM
matriptase SPD (figure 1B, diamonds). To further explore the
stability of biotin-RQRR-CMK in aqueous solution, 0.2 nM
matriptase SPD was incubated with just 5 nM biotin-RQRR-
CMK after various times of pre-incubation at 37uC. Our
experiments show that 5 nM biotin-RQRR-CMK is capable of
fully inhibiting the peptidolytic activity of 0.2 nM matriptase SPD
(figure 1C, crosses) even after 60 min of pre-incubation at 37uC
(figure 1C, circles) whereas pre-incubation for 120 min or longer
gradually reduces the efficiency of biotin-RQRR-CMK inhibition
(figure 1C, stars and diamonds). This shows that biotin-RQRR-
CMK is an efficient inhibitor of matriptase SPD and that biotin-
RQRR-CMK is sufficiently stable in aqueous solutions to conduct
the experiments described below. We have roughly estimated the
half-life of biotin-RQRR-CMK to be 25 min under the experi-
mental conditions described (data not shown).
Biotin-RQRR-CMK reacts with a subset of matriptase
molecules on the surface of cells in culture
Next, we addressed whether the biotin-RQRR-CMK peptide
inhibitor is able to bind active matriptase on the surface of cells in
culture. Differentiated Caco-2 cells express matriptase that can be
detected mainly in the SEA domain-cleaved zymogen form but
also in the Arg614-cleaved form in complex with HAI-1 [36,37].
We have previously shown that activation site cleavage of
matriptase after Arg614 takes place on the basolateral plasma
membrane of 11 days post-confluent Caco-2 cells [36] indicating
that these cells should at least momentarily contain Arg614-
cleaved matriptase not in complex with HAI-1 on the basolateral
plasma membrane if it exists. Therefore, in order to test whether
biotin-RQRR-CMK is able to bind to plasma membrane-
associated matriptase, we treated 11 days post-confluent filter-
grown Caco-2 cells with biotin-RQRR-CMK from the basolateral
side at 37uC for 2–180 min or at 4uC for 180 min. The inhibitor-
treated cells were lysed, and biotin-RQRR-CMK-labeled prote-
ases were extracted from cleared lysates using streptavidin-coated
Detection of Active Matriptase
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resin. Proteins were released from the resin by boiling in SDS
sample buffer. Due to substrate overlap of matriptase with other
trypsin-like serine proteases [33], we detected active matriptase by
Western blot analysis using a matriptase specific antibody. To
assess the steady state level of total surface-associated matriptase,
parallel cultures were surface-biotinylated with S-NHS-SS-biotin
at 4uC, whereby protein transport is inhibited. S-NHS-SS-biotin is
plasma membrane impermeable and reacts with amine groups in
an unspecific manner and therefore in this setup labels membrane-
bound proteins in general.
Matriptase endogenously expressed by Caco-2 cells binds
biotin-RQRR-CMK, as demonstrated by Western blotting
(figure 2A, lanes 4–6), and no matriptase could be detected when
labeling with a control peptide; biotin-RQRR (figure 2A, lane 2:
CTRL). This shows that matriptase is not endogenously
biotinylated. Biotin-RQRR-CMK labeling displayed time and
temperature dependence. The amount of matriptase reacting with
biotin-RQRR-CMK within a 2 min labeling time frame was
below the detection limit of the assay (figure 2A, lane 3). Likewise,
labeling with biotin-RQRR-CMK at 4uC produced no significant
signal (figure 2A, lane 7). Comparison of steady state surface-
associated matriptase as determined by biotinylation with S-NHS-
SS-biotin to the accumulated biotin-RQRR-CMK labeled
matriptase over a 30 min period or longer shows that only a
fraction of surface-associated matriptase on Caco-2 cells is able to
bind biotin-RQRR-CMK (figure 2A, compare lane 1 to lanes 4–
6). In the experiments described above, we are not able to
distinguish whether the biotin-RQRR-CMK-reactive matriptase is
present on the cell surface or whether biotin-RQRR-CMK is
endocytosed and encounters matriptase in an intracellular
compartment, as labeling was performed at 37uC. To verify that
the biotin-RQRR-CMK-reactive matriptase is present on the
plasma membrane, we performed a similar experiment, labeling
11 days post-confluent filter-grown Caco-2 cells from either the
apical or the basolateral side for 180 min at 4uC or 37uC in
triplicates and pooled the resulting cell lysates. This experiment
showed that biotin-RQRR-CMK reactive matriptase is present on
the basolateral plasma membrane at low levels, whereas reactive
matriptase could not be detected on the apical plasma membrane
of Caco-2 cells (figure 2B). Together this shows that only a fraction
of the membrane-associated matriptase on the basolateral plasma
membrane of Caco-2 cells binds biotin-RQRR-CMK. Biotin-
RQRR-CMK also reacts with other serine proteases, as prostasin
could be detected in the streptavidin pull-downs of biotin-RQRR-
CMK labeled cells when analyzed by Western blotting using a
prostasin specific antibody (data not shown), emphasizing that
specificity of the assay depends on the antibody used for the
Western blot analysis.
Biotin-RQRR-CMK does not react with the matriptase-
HAI-1 complex
After Arg614 cleavage, matriptase rapidly forms a non-covalent,
but SDS-resistant complex with HAI-1 that can be detected by
SDS-PAGE under non-reducing conditions [32]. In order to
investigate whether biotin-RQRR-CMK binds to the matriptase-
HAI-1 complex, we took advantage of the fact that cells exposed to
slightly acidic conditions have been reported to rapidly convert
matriptase from the SEA domain-cleaved form into the Arg614-
cleaved form of matriptase in complex with HAI-1 [21–23]. First,
we verified that exposure to slightly acidic conditions also converts
SEA domain-cleaved matriptase into a complex of Arg614-cleaved
matriptase with HAI-1 in Caco-2 cells. For this purpose, 11 days
Figure 1. Biotin-RQRR-CMK efficiently inhibits matriptase even after 3 hours of pre-incubation at 376C. (A) Schematic structure of the
biotin-RQRR-CMK peptide inhibitor. (B) The reactivity of biotin-RQRR-CMK was tested after 180 min of pre-incubation at 37uC (diamonds) or without
preincubation (crosses). 0.2 mM matriptase SPD was incubated for 10 min at 37uC with (diamonds and crosses) or without (squares) 50 mM biotin-
RQRR-CMK before addition of the chromogenic substrate to a final concentration of 300 mM. (C) The stability of 5 nM biotin-RQRR-CMK was further
tested after the time points 0 (crosses), 60 (circles), 120 (stars), and 180 min (diamonds) of pre-incubation at 37uC and compared to a control not
containing biotin-RQRR-CMK (squares). As described above, 0.2 nM matriptase SPD was added to each sample and incubated for 10 min at 37uC
followed by addition of the chromogenic substrate to a final concentration of 300 mM. In all cases, the enzymatic activity of SPD was monitored by
conversion of the chromogenic substrate (S2288). Each plot shows the change in optical density at 405 nm of the reaction mixture as a function of
reaction time. The presence of active protease results in a continued release of a yellow cleavage product resulting in a linear color development in
agreement with a pseudo 1st order reaction due to the high molar excess of substrate to protease. Results shown are representative of 3 independent
experiments.
doi:10.1371/journal.pone.0077146.g001
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post-confluent filter-grown Caco-2 cells were treated with phys-
iological phosphate buffer pH 6.0 for 20 min (figure 3A, lanes 2, 4,
6, and 8) or left untreated (figure 3A, lanes 1, 3, 5, and 7). The cells
were lysed and the two lysates were investigated by Western
blotting under non-boiled and non-reducing conditions (figure 3A,
lanes 1–4 and 7–8) and under reducing conditions (figure 3A, lanes
5 and 6) using different antibodies recognizing matriptase, HAI-1,
and their complex. Untreated Caco-2 cells mainly contained
matriptase that is not in complex with HAI-1 as it migrates as a
70 kDa band under non-boiled and non-reducing conditions
(figure 3A, lane 1). This material is mainly in the SEA domain-
cleaved form, as it migrates at 85 kDa under reducing conditions
(figure 3A lane 5). Caco-2 cells treated with a pH 6.0 buffer
contain matriptase mainly in complex with HAI-1, as it migrates
as 130 kDa under non-boiled and non-reducing conditions
(figure 3A, lanes 2 and 4) and can be detected using antibodies
against HAI-1 (figure 3A, lane 8). Most of this material is in the
Arg614-cleaved form, as it migrates as two bands around 25–
30 kDa under reducing conditions (figure 3A, lane 6). Thus,
treatment with physiological phosphate buffer pH 6.0 induces
cleavage of matriptase after Arg614 and complex formation with
HAI-1 in Caco-2 cells.
To investigate whether Arg614-cleaved matriptase is able to
react with biotin-RQRR-CMK at pH 6.0, we measured the
catalytic activity of matriptase SPD at this pH in the presence and
absence of biotin-RQRR-CMK in the chromogenic assay
described above (figure 1). Matriptase SPD was able to cleave
the chromogenic substrate at pH 6.0, although at a lower rate
than at neutral pH (compare figure 3B, squares to figure 1B,
squares). When 50 mM biotin-RQRR-CMK was added to the
reaction, no cleavage of the substrate was observed (figure 3B,
crosses). Thus, biotin-RQRR-CMK is still able to inhibit
matriptase SPD-mediated substrate hydrolysis at pH 6.0, which
allows us to test whether biotin-RQRR-CMK can label matriptase
in complex with HAI-1. For this purpose, we employed
physiological phosphate buffer pH 6.0 to induce cleavage of
matriptase after Arg614 and matriptase-HAI-1 complex forma-
tion. Eleven days post-confluent filter-grown Caco-2 cells were
treated with 50 mM biotin-RQRR-CMK from the basolateral side
at 37uC for 30 min under different conditions; labeling with
biotin-RQRR-CMK at pH 7.4 (figure 4, lanes 3 and 7), labeling
with biotin-RQRR-CMK in physiological phosphate buffer
pH 6.0 (figure 4, lanes 4 and 8), or pre-treatment with
physiological phosphate buffer pH 6.0 for 30 min followed by
labeling with biotin-RQRR-CMK at pH 7.4 for 30 min (figure 4,
lanes 5 and 9). Additional controls were lysates of untreated cells
(figure 4, lane 1) and cells treated with physiological phosphate
buffer pH 6.0 (figure 4, lane 2) to confirm pH 6.0 induced
complex formation between matriptase and HAI-1. In all cases,
aliquots of the total lysates (figure 4, lanes 1–5) as well as the boiled
streptavidin pull downs were analyzed in Western blot analysis
(figure 4, lanes 6–9).
Exposure to low pH clearly induced matriptase-HAI-1 complex
formation (figure 4, compare lanes 1 and 2). Biotin-RQRR-CMK
labeling of matriptase was detected when labeling was performed
at pH 7.4 (figure 4, lane 7) and pH 6.0 (figure 4, lane 8) but not
when the cells had been exposed to pH 6.0 for 30 min to induce
matriptase-HAI-1 complex formation before labeling with biotin-
RQRR-CMK figure 4, lanes 9). These results suggest that
matriptase-HAI-1 complex is not labeled with biotin-RQRR-
CMK. It was also observed that HAI-1 and biotin-RQRR-CMK
compete for binding to matriptase as reduced levels of matriptase-
HAI-1 complex is formed in the presence of biotin-RQRR-CMK
as compared to in the absence of biotin-RQRR-CMK (figure 4,
compare lanes 2 and 4). Higher levels of biotin-RQRR-CMK
reactive matriptase was observed when labeling was performed at
pH 6.0 as compared to pH 7.4 (figure 4, compare lanes 7 and 8)
despite the lower specific activity of matriptase at pH 6.0
compared to pH 7.4 (figure 1B squares compared to figure 3B
squares and [33]). Presumably cleavage of matriptase after Arg614
occurs both at pH 6.0 and at pH 7.4 albeit not at the same rate.
We interpret the increased formation of biotin-RQRR-CMK
labeling at pH 6.0 to be due to a time window between cleavage of
matriptase after Arg614 and formation of the matriptase-HAI-1
complex.
Biotin-RQRR-CMK reacts with both SEA domain-cleaved
and Arg614-cleaved matriptase
To investigate whether the biotin-RQRR-CMK reactive
matriptase present on Caco-2 cells includes both SEA
Figure 2. Biotin-RRQR-CMK reacts with a subset of matriptase molecules on the surface of Caco-2 cells. (A) Eleven days post-confluent
Caco-2 cells grown on Transwell filters were labeled with 50 mM biotin-RQRR-CMK from the basolateral side for the times indicated (2–180 min) at
37uC (lanes 3–6) or for 180 min at 4uC (lane 7). As a measure of the steady state level of matriptase, membrane proteins on the basolateral plasma
membrane of filter-grown Caco-2 cells were labeled by incubation with S-NHS-SS-biotin at 4uC for 30 min (lane 1). As a negative control, cells were
labeled from the basolateral side with 50 mM control peptide; biotin-RQRR (lane 2). All cells were lysed and biotinylated proteins were precipitated
using streptavidin-coated resin and were analyzed by non-reducing SDS-PAGE and Western blotting using the monoclonal matriptase antibody; M32.
A tenth of the surface biotinylated sample was loaded (lane 1); whereas total sample volume was loaded for the other samples (lanes 2-7). (B) Caco-2
cells grown on Transwell filters were labeled with the biotin-RQRR-CMK peptide inhibitor from either the apical (lanes 1, 4, and 7) or the basolateral
(lanes 2, 5, and 8) side for 180 min at either 4uC or 37uC. An overexposure of lanes 1–3 is shown in lanes 7–9. As a negative control, cells were labeled
from the basolateral side with a peptide corresponding to the inhibitory peptide but lacking the CMK moiety (CTRL, lanes 3, 6, and 9). Cells were lysed
and the lysates of multiple filters were pooled. Biotinylated proteins were precipitated using streptavidin-coated resin and the streptavidin pull
downs were released by boiling in SDS-PAGE samples buffer and analyzed by SDS-PAGE and Western blotting using the monoclonal M32 antibody.
Positions of the molecular weight markers (kDa) are indicated on the left. Results shown are representative of 3 independent experiments.
doi:10.1371/journal.pone.0077146.g002
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domain-cleaved and Arg614-cleaved matriptase, 11 days post-
confluent filter-grown Caco-2 cells were labeled with biotin-
RQRR-CMK from the basolateral side for 180 min at 37uC.
Biotin-RQRR-CMK labeled proteases were precipitated with
streptavidin-coated resin, and subjected to reducing SDS-PAGE.
Samples were analyzed by Western blot analysis using an antibody
against matriptase SPD (IM1014). Under reducing conditions,
matriptase could be detected both as the 70 kDa form represent-
ing SEA domain-cleaved matriptase and the 25-30 kDa forms
representing Arg614-cleaved matriptase (figure 5, lane 2). No
matriptase could be detected when labeling Caco-2 cells with the
control peptide; biotin-RQRR (figure 5, lane 1: CTRL). This
indicates that both Arg614-cleaved matriptase not in complex with
HAI-1 and the SEA domain-cleaved matriptase zymogen is
present on the basolateral plasma membrane of Caco-2 cells.
Biotin-RQRR-CMK also reacts with murine matriptase
The described assay can be easily modified to detect active
matriptase from other species, as the specificity of the assay
depends only on the antibody used. To verify this, the presence of
active matriptase was investigated in cultured primary murine
keratinocytes. Keratinocytes from the skin of matriptase wildtype
(WT) and matriptase-deficient (KO) newborn pups were isolated,
plated on collagen-coated plastic and labeled with 50 mM biotin-
RQRR-CMK at subconfluence for 180 min at 37uC or labeled
with S-NHS-SS-biotin for 30 min at 4uC to assess surface-
associated matriptase. As a negative control, keratinocytes were
labeled with biotin-RQRR. Equal aliquots of cleared lysates were
analyzed by Western blot for total matriptase, prior to streptavidin
pull down of biotinylated proteins. Proteins were released from the
streptavidin-coated resin by boiling in SDS sample buffer and
analyzed by Western blotting. While at very low levels, we were
able to detect biotin-RQRR-CMK reactive matriptase by labeling
of keratinocytes isolated from mice expressing matriptase with
biotin-RQRR-CMK (figure 6, lane 2). No matriptase was detected
when labeling with the corresponding control peptide; biotin-
RQRR (figure 6, lane 3). No matriptase could be detected in
lysates or pull downs of keratinocytes from matriptase-deficient
mice (figure 6, lanes 4–6 and 10–12), whereas matriptase was
Figure 3. Arg614-cleaved matriptase is able to form complexes with HAI-1 and biotin-RQRR-CMK at pH 6.0. (A) Eleven days post-
confluent filter-grown Caco-2 cells were treated with either a physiologically phosphate buffer pH 6.0 for 20 min (lanes 2, 4, 6, and 8) from both the
apical and the basolateral side or left untreated (lanes 1, 3, 5, and 7). Cells were lysed and lysates were analyzed by Western blotting using antibodies
against total matriptase (M24; lanes 1 and 2), matriptase SPD (IM1014; lanes 5 and 6), matriptase-HAI-1 complex (M69; lanes 3 and 4) and HAI-1 (lanes
7 and 8). Samples in lanes 1–4, 7, and 8 were not boiled to avoid dissociation of matriptase-HAI-1 complexes, while samples in lanes 5 and 6 were
boiled and reduced to dissociate the S-S bridged SPD from the stem domain of activated matriptase in order to distinguish between the SEA domain-
cleaved form (70 kDa) and the Arg614 cleaved form (25–30 kDa). Treatment with phosphate buffer pH 6.0 and DTT is indicated by +/2. Positions of
the molecular weight markers (kDa) are indicated on the left. (B) A solution of 0.2 mM SPD was incubated for 10 min at 37uC with (crosses) or without
(squares) 50 mM biotin-RQRR-CMK before addition the chromogenic substrate to a final concentration of 300 mM. All experiments were performed in
20 mM citric acid buffer pH 6.0, 140 mM NaCl and 0.1% BSA at 37uC. Results shown are representative of 3 independent experiments.
doi:10.1371/journal.pone.0077146.g003
Figure 4. Biotin-RQRR-CMK does not react with matriptase-
HAI-1 complexes. Eleven days post-confluent Caco-2 cells grown on
Transwell filters were labeled with 50 mM biotin-RQRR-CMK at pH 7.4
(lanes 3 and 7), in physiological phosphate buffer pH 6.0 (lanes 4 and 8),
or at pH 7.4 with a 30 min pre-incubation treatment with physiological
phosphate buffer pH 6.0 (lanes 5 and 9) for 30 min at 37uC. All cells
were lysed and samples of lysates were analyzed under non-boiled and
non-reducing conditions (lanes 1–5). Labeled proteases in the lysates
were precipitated using streptavidin-coated resin and released from the
beads by boiling (lanes 7–9). The streptavidin pull downs were analyzed
by SDS-PAGE and Western blotting (lanes 6–9). As a negative control,
lysate of cells treated with only physiological phosphate buffer pH 6.0
for 30 min was also streptavidin-precipitated and analyzed (CTRL, lanes
6). All lanes were analyzed using the M32 antibody. Positions of the
molecular weight markers (kDa) are indicated on the left. Results shown
are representative of 3 independent experiments.
doi:10.1371/journal.pone.0077146.g004
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easily detected in all lysates of the 3 differently treated keratinocyte
cultures from mice expressing WT matriptase (figure 6, lanes 7–9).
Comparison of S-NHS-SS biotin labeling and biotin-RQRR-
CMK labeling of WT murine keratinocytes showed that only a
fraction of surface-associated matriptase on WT keratinocytes cells
could be detected by means of biotin-RQRR-CMK (figure 6,
compare lanes 1 and 2). This suggests that biotin-RQRR-CMK
and the described assay can be applied for a range of cell systems
as well as other species when an appropriate antibody is used.
Discussion
Due to the importance of the membrane-anchored serine
protease matriptase in physiological and pathological processes [2–
4,38–43], it would be advantageous to be able to detect active
matriptase in cell culture samples in a simple and inexpensive way.
Several assays to detect active matriptase have been established,
but they are either indirect [18,36] or technical demanding, e.g.
requiring access to a 2D fluorescent imager [44].
This study describes a simple and efficient assay for detection of
active matriptase in cultured cells by combining antibody
specificity, the high affinity of the biotin-streptavidin interaction,
and a specifically designed chloromethyl ketone peptide inhibitor;
biotin-RQRR-CMK.
In the present study, live cells in culture were allowed to react
with biotin-RQRR-CMK for a period of time after which surplus
biotin-RQRR-CMK was thoroughly washed away, followed by
lysis of the cells and isolation and analysis of the biotinylated
proteins. It is therefore unlikely, that activation of matriptase and/
or labeling occurs after lysis of the cells. We have used Caco-2 cells
as a model in the present study since Caco-2 cells have an
endogenous expression of matriptase and all necessary auxiliary
proteins required for matriptase activation. We have previously
shown that cleavage of matriptase after Arg614 takes place on the
basolateral plasma membrane of 11 days post confluent Caco-2
cells [36], confirming that matriptase is activated in these cells.
Recent studies show that the SEA domain-cleaved zymogen
form of matriptase is at least partially biologically active
[13,14,45]. It is accepted that the zymogen form of serine
proteases can exhibit proteolytic activity without being proteolyt-
ically activated. Zymogen activity is described by the zymogenicity
factor, which is the ratio between the catalytic efficiency of the
activated form and the zymogen form. The zymogenicity for most
proteases is in the range of 103–106, which means that the
zymogen is virtually inactive [46]. However, for some proteases
the zymogenicity is as low as 3–9 as seen for tPA [47–51]. The
zymogenicity for rat matriptase towards a small model substrate in
vitro has been determined to 27 [13,14,52]. This suggests that the
zymogen form of matriptase has significant proteolytic acitivity. It
is generally believed that zymogens as in the case of matriptase
alternates between different conformations, one in which the
conformation of the active site and underlying catalytic machinery
resemble that of the active enzyme [51] and it can therefore be
expected that only part of the SEA-domain cleaved zymogen
matriptase is in the active conformation.
We would ideally prefer the assay to detect the Arg614-cleaved
form of matriptase in addition to the active SEA domain-cleaved
zymogen form, but not the inactive SEA domain-cleaved form and
not the inhibitor-bound form of matriptase.
We clearly show that biotin-RQRR-CMK reacts with the
Arg614-cleaved form of matriptase, as represented by both
purified SPD and matriptase endogenously expressed by Caco-2
cells. Biotin-RQRR-CMK inhibits matriptase SPD-mediated
substrate hydrolysis and biotin-RQRR-CMK-labeled matriptase
can be detected as 25–30 kDa bands under boiling and reducing
conditions from lysates of 11-days post confluent Caco-2 cells as
would be expected of Arg614-cleaved matriptase (figure 5, lane 2).
We have previously shown that at steady state, matriptase
expressed by 11 days post confluent Caco-2 cells is primarily
present on the plasma membrane [36] and mainly present in the
SEA domain-cleaved zymogen form (figure 3, lane 5). Our results
show that biotin-RQRR-CMK reacts with the SEA domain-
cleaved matriptase, as labeling of Caco-2 cells with biotin-RQRR-
CMK also result in a 85 kDa band under boiled and reducing
conditions as would be expected for the active SEA domain-
cleaved matriptase.
Biotin-RQRR-CMK is an efficient inhibitor of matriptase at the
concentrations used and biotin-RQRR-CMK and NHS-SS-biotin
have approximately the same molecular weight and half-life.
However, even though we detected an efficient labeling of
matriptase on the basolateral plasma membrane with NHS-SS-
biotin, only low levels of biotin-RQRR-CMK-reactive matriptase
could be detected. This suggests that large amount of SEA
domain-cleaved matriptase was present and accessible but only a
fraction of it in a biotin-RQRR-CMK reactive form. Our
interpretation of this is that biotin-RQRR-CMK only reacts with
the ‘‘active’’ form SEA domain-cleaved zymogen form of
Figure 5. Biotin-RQRR-CMK detects both SEA domain-cleaved
zymogen matriptase and Arg614-cleaved matriptase. Eleven
days post-confluent Caco-2 cells grown on Transwell filters were labeled
with 50 mM biotin-RQRR-CMK from the basolateral side for 180 min at
37uC. As a negative control, cells were labeled from the basolateral side
with 50 mM control peptide; biotin-RQRR (CTRL), under the same
conditions. Labeled proteases were precipitated using streptavidin-
coated resin and the streptavidin pull downs were analyzed by
reducing SDS-PAGE and Western blotting using the IM1014 antibody
raised against matriptase SPD. Positions of the molecular weight
markers (kDa) are indicated on the left and position of SEA domain-
cleaved zymogen matriptase and matriptase SPD is indicated on the
right. Results shown are representative of 3 independent experiments.
doi:10.1371/journal.pone.0077146.g005
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matriptase, which only constitute a fraction of the total SEA
domain-cleaved matriptase.
The biotin-RQRR-CMK seems not to react with matriptase in
complex with HAI-1. We show that SEA domain-cleaved
matriptase after exposure to pH 6.0 for 30 min at 37uC efficiently
induces activation of matriptase and matriptase-HAI-1 complex
formation. We have previously shown that endocytosis of
biotinylated matriptase-HAI-1 complex from the basolateral
plasma membrane of 11 days post-confluent Caco-2 cells takes
more than an hour [36]. In the present study, a 30 min incubation
at pH 6.0 was needed for maximum matriptase-HAI-1 complex
formation to take place which was followed by treatment with
biotin-RQRR-CMK. We therefore expect that at least part of the
matriptase-HAI-1 complex formed after exposure to pH. 6.0 for
30 min were exposed to biotin-RQRR-CMK suggesting that
matriptase-HAI-1 does not bind the biotin-RQRR-CMK inhib-
itor.
Thus the data suggest that the biotin-RQRR-CMK peptide
reacts with two active forms of matriptase; the Arg614-cleaved
form and the active SEA domain-cleaved form but not the inactive
SEA domain uncleaved form and not with the matriptase-HAI-1
complex.
For most proteases, the serine protease domain cleaved form is
also the biologically active form. However, we recently showed
that zymogen-locked matriptase is able to activate prostasin [45].
This suggests that at least under some circumstances the SEA
domain-cleaved zymogen form of matriptase is the biologically
active form. It has been difficult experimentally to detect the non-
complexed Arg614-cleaved active form of matriptase [21,53]. This
is probably due to a low abundance of non-complexed Arg614-
cleaved active matriptase. However, data obtained in the present
study suggests that Arg614-cleaved matriptase not in complex with
HAI-1 does exist albeit at very low concentrations as biotin-
RQRR-CMK clearly binds Arg614-cleaved matriptase. For some
time it was speculated that the matriptase-HAI-1 complex was
formed before or concomitantly with matriptase cleavage after
Arg614. However, when comparing biotin-RQRR-CMK labeling
at pH 7.4 with labeling at pH 6.0 it is clear that even though
matriptase activity is lower at pH 6.0 (figure 3B squares, [33]) than
at pH 7.4 (figure 1B squares) more matriptase reacts with biotin-
RQRR-CMK at pH 6.0. This suggests that a time window exists,
in which reaction with biotin-RQRR-CMK can take place,
subsequent to matriptase cleavage after Arg614 and before the
matriptase-HAI-1 complex is formed.
We found that HAI-1 and biotin-RQRR-CMK compete for
binding to matriptase. This corresponds well with the recently
published structure of matriptase in complex with HAI-1 showing
that Kunitz domain 1 of the protease inhibitor interacts with the
substrate binding cleft of matriptase [28]. Furthermore, although
HAI-1 binds matriptase in a reversible, but yet very stable manner,
biotin-RQRR-CMK is not able to dissociate the matriptase-HAI-1
complex under the conditions used in the study although biotin-
RQRR-CMK is present at high concentrations.
The presence of Arg614 cleaved matriptase as detected by
analysis of total cell lysates by western blot under reducing
conditions using the IM1014 antibody indicates the amount of
Arg614 cleaved matriptase present in the sample, but not whether
the Arg614 cleaved matriptase is unbound and active or if
matriptase is bound to HAI-1 and therefore inactive. Actually in
some cases low amount of Arg614 cleaved matriptase can be
detected (figure 3, lane 5) of which some reacts with biotin-
RQRR-CMK indicating that active matriptase is present (figure 4,
lane 7). Whereas the same cells after exposure to pH 6.0 contains
larger amounts of Arg614 cleaved matriptase (figure 3, lane 6) of
which no biotin-RQRR-CMK reactive matriptase can be detected
(figure 4, lane 9) indicating the absence of active matriptase. In
contrast to analysis of the total lysate using IM1014 on Western
blots, the biotin-RQRR-CMK assay offers the possibility to detect
(and distinguish between) the active SEA domain-cleaved zymo-
gen form and the non-complexed Arg614-cleaved form of
matriptase.
In summary, we have established an assay for detection of active
matriptase on cells in culture. The availability of a simple and
inexpensive assay for detection of active matriptase may help us
understand the complex regulation of matriptase activity. The
assay described here can be transferred to other species as shown
by detection of active matriptase in primary cultures of mouse
keratinocytes.
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Figure 6. Detection of active matriptase in cultured primary murine keratinocytes. Murine keratinocytes were isolated from newborn
wildtype (WT) or matriptase-deficient pups (KO) and cultured on collagen-coated plastic. The cells were grown until sub-confluent and then labeled
with S-NHS-SS-biotin (lanes 1, 4, 7, and 10), or with 50 mM biotin-RQRR-CMK (lanes 2, 5, 8, and 11), or with 50 mM control peptide; biotin-RQRR (lanes
3, 6, 9, and 12). Cells were lysed and analyzed on Western blot (lanes 7–12). The remaining lysates were precipitated using streptavidin-coated resin,
released from the beads by boiling under non-reducing conditions and lysates were analyzed by SDS-PAGE and Western blotting using the
matriptase antibody AF3946. Results shown are representative of 2 independent experiments.
doi:10.1371/journal.pone.0077146.g006
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